An open-label, single-arm, global Phase II clinical trial investigated the safety and efficacy of the combination therapy of balstilimab (anti-PD-1 antibody) and zimberelimab (anti-PD-1 antibody) in patients with advanced cervical cancer [73]. Here, PDCD1 is linked to cervical carcinoma.